Sr. Medical Director, Infectious Diseases Clinical Development, AbbVie
Infectious Disease
Dr. Nancy S. Shulman, MD
|
|
Give Review
Dr. Nancy S. Shulman practices Infectious Disease. She attended University of Kansas School of Medicine. Dr. Nancy S. Shulman is a published doctor and has 31 publications published. The lastest was: 'An anterior mediastinal mass with draining sternal sinus tracts due to Nocardia braziliensis.'
Publications
- Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
- DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
- Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
- The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized trial.
- Effect of IL28B Genotype on Early Viral Kinetics during Interferon-Free Treatment of Patients with Chronic Hepatitis C.
- Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
- Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.
- Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patie...
- More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175.
- Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor mutations: phenotypes and mechanisms.
- Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
- Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays.
- Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
- Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
- Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-b...
- Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
- Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
- Genetic correlates of efavirenz hypersusceptibility.
- Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
- Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efa...
- Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.
- Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.
- A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors.
- Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.
- Case files from Stanford University Medical Center: ten years of HAART: a long wait for full HIV suppression.
- NNRTI hypersusceptibility.
- Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.
- Antiretroviral rounds. When to rock the boat?
- An anterior mediastinal mass with draining sternal sinus tracts due to Nocardia braziliensis.
- Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep...
Schools
University of Kansas School of Medicine
University Chicago Pritzker School Med
Stanford University
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Stanford University -
University of Chicago -
University of Kansas School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Karen M. Starko, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vivian Levy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dennis M. Israelski, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Gisela F. Schecter, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Bouke C. Dejong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa Gooze, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cybele A. Renault, MD |
|
|
Dr. Karen Relucio, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeanne A. Linquist, MD
This Doctor is OpenDoctor Recommended.
|